Results 161 to 170 of about 131,822 (267)

Correction: CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality. [PDF]

J Psychiatry Neurosci
Gobbi G.
europepmc   +1 more source

TRP canonical 4 and/or 5 channel inhibition reduces aversion‐ and increases reward‐responding in chronically stressed mice

British Journal of Pharmacology, Volume 183, Issue 9, Page 2139-2165, May 2026.
Abstract Background and Purpose Pharmacological inhibition of TRPC4 and/or TRPC5 channels reduces Pavlovian aversion memory in stressed mice and reduces amygdala reactivity to aversion in humans with depression. The aims of this mouse study were to improve understanding of these anxiolytic processes, determine whether there are corrective effects on ...
Giulia Poggi, Deniz Queisser, Alena Senn, Hannes Sigrist, Diana Kúkeľová, Lorraine Madur, Nagiua Cuomo‐Haymour, Mélisse Robert, Sophie Schmid, Adrián Portalés, Sophie Simard, Naguib Mechawar, Bastian Hengerer, Stefan Just, Christopher R. Pryce   +14 more
wiley   +1 more source

Correction to: Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. [PDF]

Psychopharmacology (Berl)
Rose JE, Frisbee S, Campbell D, Salley A, Claerhout S, Davis JM.   +5 more
europepmc   +1 more source

Effect of a Single Oral Dose of Dexamphetamine or Zolpidem on Attention and Reaction Time in Healthy Men

Fundamental &Clinical Pharmacology, Volume 40, Issue 3, May 2026.
ABSTRACT Psychotropic medicines are known to impair cognitive function acutely, but the specific effects of individual substances remain underexplored. This study investigates the effects of dexamphetamine and zolpidem on cognitive performance to quantify the potential risk of intake and their pharmacokinetic and pharmacodynamic relationship.
Veronika Pfoser‐Poschacher, Michael Wolf, Michaela Bayerle‐Eder, Teresa Wimmer, Daniela Boryshchuk, Christopher Gerner, Michael Wolzt   +6 more
wiley   +1 more source

Authors response to nitrous oxide and mood: metabolic mechanisms (E. H. Reynolds). [PDF]

EBioMedicine
Gill K, de Cates AN, Morales-Muñoz I, Marwaha S.   +3 more
europepmc   +1 more source

Psychobiotics and the microbiota–gut–brain axis: Emerging paradigms in mental health modulation

Experimental Physiology, Volume 111, Issue 5, Page 2449-2463, 1 May 2026.
Abstract The global rise in mental health conditions has prompted interest in interventions that act beyond conventional psychopharmacology. Psychobiotics, broadly understood as live microorganisms or microbe‐derived products that interact with the microbiota–gut–brain axis, have been suggested to exert neuroactive effects through neural, immune ...
Amir Arsalan Ghahari, Mehrdad Nourizadeh, Mehrdad SalekShahabi, Shaghayegh Davari, Saeid Mohammadzadeh Mounesyar   +4 more
wiley   +1 more source

Treatment and Pharmacology of Anxiety From Classical Antiquity to the Present Day: Methods and Therapeutic Practices. [PDF]

Cureus
Sideris P, Michaleas SN, Karamanou M, Vlachakis GN.   +3 more
europepmc   +1 more source

Welcoming 2026: Broadening Clinical Perspectives. [PDF]

Clin Psychopharmacol Neurosci
Pae CU.
europepmc   +1 more source

Correction to: Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. [PDF]

Psychopharmacology (Berl)
Borgogna NC, Owen T, Petrovitch D, Vaughn J, Johnson DAL, Pagano LA, Aita SL, Hill BD.   +7 more
europepmc   +1 more source

Correction to: Infuence of real-world cue exposure and mood states on drinking: testing neurobiological models of alcohol use disorder. [PDF]

Psychopharmacology (Berl)
Meredith LR, Baskerville WA, Lee C, Grodin EN, Wassum KM, Ray LA.   +5 more
europepmc   +1 more source